Syntara Limited has released a press release.
Appendix 4E and Annual Report to shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Half Yearly Report and Accounts
- PXS Company Restructure Sale of Mannitol Business
- PXS to Receive Prepayment of 2023 Research Tax Incentive
- Final Set of Interim Data from PXS-5505 in Myelofibrosis
- PXS Announces Encouraging Results from Phase 1c Scar Study
Later from Syntara
- Pause in Trading
- Response to ASX Price Query
- Trading Halt
- Presentation: Phase 2 study of SNT-5505 in myelofibrosis
- Interim data in Phase 2 study of SNT-5505 in myelofibrosis
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara